Factors associated with delayed presentation to healthcare facilities for Lassa fever cases, Nigeria 2019: a retrospective cohort study

Nastassya L. Chandra1,2*, Hikaru Bolt2, Chioma Dan-Nwafor3, Oladipupo Ipadeola3, Elsie Ilori3, Geoffrey Namara3,4, Adelola T. Olayinka3,4, Winifred Ukponu5, Akanimo Iniobong3, Michael Amedu3, Adejoke Akano3, Kachikwulu O. Akabike3, Uwaifiokun Okhuaro6, Stephen Fagbemi7, Emeka Sampson8, Sophie Newitt9, Neville Q. Verlander7, Daniel G. Bausch2, Olivier le Polain de Waroux2 and Chikwe Ihekweazu3

Abstract

Background: Large outbreaks of Lassa fever (LF) occur annually in Nigeria. The case fatality rate among hospitalised cases is ~ 20%. The antiviral drug ribavirin along with supportive care and rehydration are the recommended treatments but must be administered early (within 6 days of symptom onset) for optimal results. We aimed to identify factors associated with late presentation of LF cases to a healthcare facility to inform interventions.

Methods: We undertook a retrospective cohort study of all laboratory confirmed LF cases reported in Nigeria from December 2018 to April 2019. We performed descriptive epidemiology and a univariate Cox proportional-hazards regression analysis to investigate the effect of clinical (symptom severity), epidemiological (age, sex, education, occupation, residential State) and exposure (travel, attendance at funeral, exposure to rodents or confirmed case) factors on time to presentation.

Results: Of 389 cases, median presentation time was 6 days (IQR 4–10 days), with 53% attending within 6 days. There were no differences in presentation times by sex but differences were noted by age-group; 60+ year-olds had the longest delays while 13–17 year-olds had the shortest. By sex and age, there were differences seen among the younger ages, with 0–4-year-old females presenting earlier than males (4 days and 73% vs. 10 days and 30%). For 5–12 and 13–17 year-olds, males presented sooner than females (males: 5 days, 65% and 3 days, 85% vs. females: 6 days, 50% and 5 days, 61%, respectively). Presentation times differed across occupations 4.5–9 days and 20–60%, transporters (people who drive informal public transport vehicles) had the longest delays. Other data were limited (41–95% missing). However, the Cox regression showed no factors were statistically associated with longer presentation time.

(Continued on next page)
Factors, including sex, age, rurality, and socio-economic status, are associated with many outcomes. Delays in presentation to a healthcare facility were associated with many outcomes in Africa. The case fatality rate (CFR) among people presenting later to healthcare facilities may impact survival. Studies on tuberculosis and trypanosomiasis in Africa have reported that delays in presentation to healthcare facilities, suggesting that time to presentation may indeed be a key intervention point to reduce mortality. Studies on tuberculosis and trypanosomiasis in Africa have shown a higher CFR among people presenting later to healthcare facilities, suggesting that time to presentation may indeed be a key intervention point to reduce mortality. Studies on tuberculosis and trypanosomiasis in Africa have shown a higher CFR among people presenting later to healthcare facilities, suggesting that time to presentation may indeed be a key intervention point to reduce mortality.

Keywords: Lassa fever, Nigeria, Surveillance, Epidemiology, Delayed presentation, Healthcare, Retrospective cohort study

Background
Lassa fever (LF) infection is a viral haemorrhagic fever (VHF) caused by a single stranded RNA virus belonging to the genus *Mammarenavirus*. *Lassa mammarenavirus* is transmitted to humans via contact with food or household items contaminated with rodent urine or faeces, particularly a rodent of the genus *Mastomys*, commonly known as the multimammate rat. *Lassa mammarenavirus* may also be spread between humans through direct contact with the blood, urine, faeces, or other bodily secretions of an infected person [1, 2]. However, secondary attack rates are generally less than 5% [1–3].

Lassa fever is endemic in Nigeria, with a seasonal pattern, peaking in the dry season (November to April) [3]. Recent years have seen an increase in the incidence of LF reported in Nigeria [3, 4]. Between January and May 2019, there were 578 confirmed cases in 21 states with a case fatality rate (CFR) of approximately 22%, surpassing the total case counts in 2017 and 2018 [5–7].

The incubation period of LF ranges from 2 to 21 days [2]. The onset of the disease, when symptomatic, is usually gradual, starting with non-specific symptoms then developing to more severe symptoms (including haemorrhage) after a week or so. The case fatality rate (CFR) among hospitalised cases is approximately 20%, but mild or asymptomatic infection is common [1–3].

Early treatment is considered vital in LF and delays in presentation to healthcare facilities may impact survival. Current recommended treatment is largely supportive (rehydration and symptomatic treatment). Although controversy exists over its efficacy, intravenous administration of the antiviral drug ribavirin has long been considered the standard of care, with one study showing the most impact on survival if given within the first 6 days after symptom onset [1–3, 8–10].

Investigation of the 2018–19 LF outbreak in Nigeria showed a higher CFR among people presenting later to healthcare facilities, suggesting that time to presentation and treatment may indeed be a key intervention point to reduce mortality. Studies on tuberculosis and trypanosomiasis in Africa have reported that delays in presentation to a healthcare facility were associated with many factors, including sex, age, rurality, and socio-economic status [11–13]. Informed by these studies and the three delays model [14, 15], we hypothesised that similar factors play an important role in delayed presentation time for people with LF.

To inform public health interventions including targeted health education, risk communication and preventative measures, it is important to identify factors that are associated with cases presenting later to healthcare facilities. We aimed to examine whether there are demographic, exposure, or clinical factors associated with delayed presentation of people with LF to a healthcare facility in Nigeria.

Methods
We undertook a retrospective cohort study of all laboratory confirmed LF cases reported through routine national outbreak surveillance data in Nigeria with onset dates between December 2018 and April 2019.

Data collection and management
During this period, national routine surveillance for LF comprised data from laboratory, case management (clinical) and case investigation (epidemiological) forms. The forms captured demographic information (age, sex, residential address, occupation), date of admission, hospital name, clinical details (date of symptom onset, symptoms) and exposures (contact with known or suspected LF case, being part of a contact tracing list, history of travel, direct contact with rodents or rodent faeces and urine, participation in burial activity).

The case management forms were completed at the healthcare facility that the case presented to. Specimen samples were tested at the laboratories at the Federal Teaching Hospital Abakaliki (FETHA), Irrua Specialist Teaching Hospital (ISTH), Lagos University Teaching Hospital (LUTH), Federal medical Centre Owo LF Laboratory and the National Reference Laboratory (NRL) Gaduwa. Average turnaround time of the diagnostic results is 48 h, ranging between 24 to 96 h. Turnaround time is largely dependent on the proximity of the state to the testing laboratory. The testing laboratory and a Local Government Area (LGA) Disease Surveillance and Notification Officer or State Epidemiologist entered the
data into a line list and/or in the Surveillance Outbreak Response Management and Analysis System (SORMAS) platform (implemented in 12 states). An LGA is an administrative geographical division of a state. There are 774 LGAs across the 36 states of Nigeria and the Federal Capital Territory (Fig. 1) [16]. The Nigeria Centre for Disease Control managed and linked the data.

Data cleaning and analysis
Data were de-duplicated and anonymised in Stata 14. Presentation time was defined as the difference, in days, between date of symptom onset and date of presentation at a healthcare facility. Considering biological plausibility, only those with a presentation time between 1 and 21 days were included.

Clinical symptoms were categorised as mild or severe based on LF literature [17, 18]. If a case had mild and severe symptoms, they would be categorised as severe if a case had only mild symptoms they would be categorised as mild. For example, headache, slight fever, general malaise and weakness would be categorised as a mild symptoms and haemorrhaging (in gums, eyes, or nose, as examples), respiratory distress, repeated vomiting, facial swelling, pain in the chest, back, and abdomen, and shock would be categorised as severe symptoms [17, 18]. Rurality of residence was based on the residential LGA mapped to a rurality index table (rural, semi-urban and urban) [19, 20]. Age data were grouped based on life stages (0–4, 5–12, 13–17, 18–25, 26–59 and 60+ year-olds). Sex and age-groups were looked at separately and together.

Malaria is highly prevalent in some areas of Nigeria and early symptoms of LF are similar (e.g. fever, headaches, vomiting) [21]. Understandably, people may incorrectly assume early symptoms of LF are those of malaria which may affect time to presentation. Malaria prevalence category was based on the findings of the Nigeria Malaria Indicator Survey (2015). We used the prevalence in children as a proxy for malaria prevalence in the cases’ state of residence [16].

To assess completeness, the proportion of missing data was calculated. To determine if missing data were completely at random, a mixed effects logistical regression for age-group and sex was undertaken.
We described the time to presentation (range, interquartile range, median time in days) and the number of cases that attended a healthcare facility within 6 days or less following symptom onset by demographic, clinical and exposure factors. We undertook a univariate analysis using a Cox Proportional-Hazards regression model to investigate the effect of each variable on the time to presentation. The Proportional Hazard assumption was tested on the basis of Schoenfeld residuals after fitting the Cox regression model.

Characteristics of people attending healthcare facilities in certain LGAs may be more similar e.g. a higher proportion of farmers in more rural LGAs. We accounted for LGA level clustering using a multi-level model to include the random effects of LGA to attending a healthcare facility.

For all models, 95% confidence intervals and p-values were calculated using the Wald test. A multivariable analysis was not performed following the univariate Cox Proportional-Hazards analysis, as no variables had a p-value of < 0.2, an a priori requirement.

Ethics
Ethical committee clearance was provided to undertake this study which uses retrospective routine data collected as part of LF surveillance in Nigeria, further details provided below.

Results
Descriptive epidemiology
Of 499 confirmed LF cases in the dataset, 417 (84%) had complete dates for symptom onset and attendance at a healthcare facility. Of these, 389 (78% of all cases) had presentation dates between 1 and 21 days, and thus comprised our dataset for analysis.

The median time to presentation to a healthcare facility was 6 days (Inter quartile range [IQR] 4–10 days), with 53.4% attending in 6 days or less (Table 1). Males and females had the same median time to presentation (6 days).

By age-group only, median presentation time ranged between 5 and 7 days with 45.2 to 71.0% of cases presenting within 6 days of onset.

By sex, there were differences seen among the younger age-groups, with 0–4 year-old females presenting earlier than males (females: 4 days [IQR 3–7 days] and 73%, males: 10 days [IQR 5–15] and 30%). For 5–12 and 13–17 year-olds, males had a shorter median presentation time and higher proportion presenting within 6 days of onset compared to females (males aged 5–12 years: 5 days [IQR 4–8], 65% and males aged 13–17 years: 3 days [IQR 3–6], 85%; females aged 5–12 years: 6 days [IQR 3–7], 50% and females aged 13–17: 5 days [IQR 2–9], 61%).

Most cases in the dataset came from Edo (44.0%) and Ondo (22.4%) States, who had median presentation times of 6 days. The longest presentation times were seen in Cross River (15 days) and Nasarawa (14.5 days, [IQR 8–21]) but case numbers were small. Most cases resided in rural areas (61.2%). Approximately 50% of cases in each rurality index category attended within 6 days.

Cases living in areas with the lowest malaria prevalence category (0–11%) had the longest median presentation time of 8 days (IQR 6–10) and 25% (1 case) attended within 6 days.

By occupation, transporters (people who drive informal public transport vehicles) had the longest median presentation time (9 days [IQR 7–10]) closely followed by those not working/retired (8.5 days [IQR 3–12]).

Data for education status and symptoms were limited (77.9 and 62.7% missing). Exposure data was poorly completed (between 40.6 and 94.9% missing, with the exception of travel history, for which only 6.2% were missing). Where information was available for travel history, people who had a travel history had the same median time to presentation as those who did not have a history of travel (6 days).

Missing data analysis
When comparing age groups for those with missing presentation time to those without missing presentation time, there was no statistical evidence of a difference (p-value 0.77). When comparing by sex, there was evidence of a difference, with females less likely to have missing presentation times than males (odds ratio 0.57, 95%CI 0.34–0.95, p-value 0.03).

Univariate analysis
There was no statistically significant difference between any variable with regard to time to presentation to a healthcare facility (Table 2). The proportional hazard assumption was met for all variables at the 5% significant level.

Discussion
Multiple factors may contribute to a delayed presentation to a healthcare facility and seeking early treatment and care for LF. This increases the likelihood of severe illness and death. Our study showed that almost half of all confirmed cases presented to a healthcare facility 6 days after symptom onset, but we did not find any specific factors statistically associated with delayed presentation of confirmed cases. This suggests that there is need for more public health action and messaging around LF and seeking healthcare.

We found that particular groups have longer median presentation times or present less often within 6 days of onset.
Table 1  Lassa fever case characteristics and time to presentation, Nigeria 2019, (n = 389)

| Characteristic | Stratum                  | Number of cases (%) | Number of cases attending in 6 or less days (%) | Median time to presentation (days) | Interquartile range of time to presentation (days) | Range of time to presentation (days) |
|----------------|--------------------------|---------------------|-----------------------------------------------|----------------------------------|-----------------------------------------------|-----------------------------------|
| Case definition number of cases | Laboratory Confirmed     | 389                 | 208 (53.4)                                    | 6                                | 4–10                                          | 1–21                              |
| Sex            | Female                   | 181 (46.5)          | 101 (55.8)                                    | 6                                | 3–10                                          | 1–21                              |
|                | Male                     | 207 (53.2)          | 107 (51.7)                                    | 6                                | 4–10                                          | 1–21                              |
|                | Unknown                  | 1 (0.3)             | 0                                              | 7                                | n/a                                           | n/a                               |
| Age group (years) | 0–4                     | 21 (5.4)            | 11 (52.4)                                     | 6                                | 4–13                                          | 1–16                              |
|                | 5–12                     | 35 (9.0)            | 20 (57.1)                                     | 6                                | 4–9                                           | 1–21                              |
|                | 13–17                    | 31 (8.0)            | 22 (71.0)                                     | 5                                | 2–8                                           | 1–21                              |
|                | 18–25                    | 56 (14.4)           | 33 (58.9)                                     | 6                                | 3–10                                          | 1–21                              |
|                | 26–59                    | 214 (55.0)          | 107 (50.0)                                    | 6                                | 4–10                                          | 1–21                              |
|                | 60+                      | 31 (8.0)            | 14 (45.2)                                     | 7                                | 3–10                                          | 1–14                              |
|                | Unknown                  | 1 (0.3)             | 1 (100)                                       | 4                                | n/a                                           | n/a                               |
| Age group (years) and Sex (n = 387) | Males (n = 206) | 10 (4.9) | 3 (30.0) | 10 | 5–15 | 3–16 |
|                | 5–12                     | 17 (8.3)            | 11 (64.7)                                     | 5                                | 4–8                                           | 1–20                              |
|                | 13–17                    | 13 (6.3)            | 11 (84.6)                                     | 3                                | 3–6                                           | 2–21                              |
|                | 18–25                    | 27 (13.1)           | 16 (59.3)                                     | 6                                | 3–10                                          | 1–16                              |
|                | 26–59                    | 123 (59.7)          | 59 (48.0)                                     | 7                                | 5–10                                          | 1–21                              |
|                | 60+                      | 16 (7.8)            | 6 (37.5)                                      | 7                                | 2–10                                          | 1–14                              |
|                | Unknown                  | 1 (0.3)             | 1 (100)                                       | 4                                | n/a                                           | n/a                               |
| Age group (years) and Sex (n = 387) | Females (n = 181) | 11 (6.1) | 8 (72.7) | 4 | 3–7 | 1–14 |
|                | 5–12                     | 18 (9.9)            | 9 (50)                                        | 6                                | 4–10                                          | 1–21                              |
|                | 13–17                    | 18 (9.9)            | 11 (61.1)                                     | 5                                | 2–9                                           | 1–18                              |
|                | 18–25                    | 29 (16)             | 17 (58.6)                                     | 6                                | 3–12                                          | 1–21                              |
|                | 26–59                    | 90 (49.7)           | 48 (53.3)                                     | 6                                | 4–12                                          | 1–20                              |
|                | 60+                      | 15 (8.3)            | 8 (53.3)                                      | 6                                | 3–10                                          | 1–14                              |
| Mortality status outcome | Alive       | 324 (83.3)          | 175 (54.0)                                    | 6                                | 4–10                                          | 1–21                              |
|                | Deceased                | 65 (16.7)           | 33 (50.8)                                     | 6                                | 3–10                                          | 1–19                              |
| State of residence | Abia*       | 0                  | n/a                                           | n/a                              | n/a                                           | n/a                               |
|                | Adamawa                 | 0                  | n/a                                           | n/a                              | n/a                                           | n/a                               |
|                | Akwa Ibom*              | 0                  | n/a                                           | n/a                              | n/a                                           | n/a                               |
|                | Anambra*                | 0                  | n/a                                           | n/a                              | n/a                                           | n/a                               |
|                | Bauchi                  | 36 (9.3)            | 13 (36.1)                                     | 8                                | 6–13                                          | 1–21                              |
|                | Bayelsa*                | 0                  | n/a                                           | n/a                              | n/a                                           | n/a                               |
|                | Benue                   | 4 (1.0)             | 1 (25.0)                                      | 8                                | 6–10                                          | 5–11                              |
|                | Borno*                  | 0                  | n/a                                           | n/a                              | n/a                                           | n/a                               |
|                | Cross River             | 1 (0.3)             | 0                                             | 15                               | n/a                                           | n/a                               |
|                | Delta                   | 2 (0.5)             | 0                                             | 13.5                             | 13–14                                         | 13–14                             |
|                | Ebonyi                  | 33 (8.5)            | 14 (42.4)                                     | 7                                | 4–10                                          | 1–14                              |
|                | Edo                     | 171 (44.0)          | 94 (55.0)                                     | 6                                | 4–10                                          | 1–21                              |
|                | Enugu                   | 0                  | n/a                                           | n/a                              | n/a                                           | n/a                               |
|                | Ekit*                   | 0                  | n/a                                           | n/a                              | n/a                                           | n/a                               |
|                | Federal Capital         | 1 (0.3)             | 0                                             | 11                               | n/a                                           | n/a                               |
Table 1  Lassa fever case characteristics and time to presentation, Nigeria 2019, \((n = 389)\) (Continued)

| Characteristic                  | Stratum | Number of cases (%) | Number of cases attending in 6 or less days (%) | Median time to presentation (days) | Interquartile range of time to presentation (days) | Range of time to presentation (days) |
|--------------------------------|---------|---------------------|-----------------------------------------------|----------------------------------|--------------------------------------------------|-----------------------------------|
| Territory                      |         |                     |                                               |                                  |                                                  |                                   |
| Gombe                          | 1 (0.3) | 1 (100)             | 4                                             | n/a                              | n/a                                              | n/a                               |
| Imo*                           | 1 (0.3) | 0                   | 8                                             | n/a                              | n/a                                              | n/a                               |
| Jigawa*                        | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |
| Kaduna                         | 3 (0.8) | 2 (66.7)            | 5                                             | 3–20                             | 3–20                                             |                                    |
| Kano                           | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |
| Katsina*                       | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |
| Kebbi                          | 1 (0.3) | 1 (100)             | 3                                             | n/a                              | n/a                                              | n/a                               |
| Kogi                           | 2 (0.5) | 0                   | 10                                            | 8–12                             | 8–12                                             |                                    |
| Kwara                          | 1 (0.3) | 1 (100)             | 2                                             | n/a                              | n/a                                              | n/a                               |
| Lagos*                         | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |
| Nasarawa                       | 2 (0.5) | 0                   | 14.5                                          | 8–21                             | 8–21                                             |                                    |
| Niger*                         | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |
| Ogun*                          | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |
| Ondo                           | 87 (22.4)| 58 (66.7)          | 6                                             | 3–7                              | 1–20                                             |                                    |
| Osun*                          | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |
| Oyo                            | 1 (0.3) | 1 (100)             | 5                                             | n/a                              | n/a                                              | n/a                               |
| Plateau                        | 27 (6.9)| 13 (48.2)           | 7                                             | 2–13                             | 1–20                                             |                                    |
| Rivers                         | 1 (0.3) | 1 (100)             | 4                                             | n/a                              | n/a                                              | n/a                               |
| Sokoto*                        | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |
| Taraba                         | 14 (3.6)| 8 (57.1)            | 6                                             | 5–14                             | 2–20                                             |                                    |
| Yobe*                          | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |
| Zamfara*                       | 0       | n/a                 | n/a                                           | n/a                              | n/a                                              | n/a                               |

**Rurality category (based on state of residence and information from state guidance)**

| Rurality category | Number of cases (%) |
|-------------------|---------------------|
| Rural             | 238 (61.2)          |
| Semi-urban        | 14 (3.6)            |
| Urban             | 134 (34.4)          |
| Unknown           | 3 (0.8)             |

**Malaria Prevalence category**

| Malaria Prevalence category | Number of cases (%) |
|-----------------------------|---------------------|
| 0–11%                       | 4 (1.0)             |
| 12–21%                      | 298 (76.6)          |
| 22–29%                      | 3 (0.8)             |
| 30–36%                      | 62 (15.9)           |
| 37–64%                      | 22 (5.7)            |

**Education status**

| Education status | Number of cases (%) |
|------------------|---------------------|
| Primary          | 20 (5.1)            |
| Secondary        | 32 (8.2)            |
| Tertiary         | 35 (9.0)            |
| Unknown          | 302 (77.6)          |

**Occupation group**

| Occupation group | Number of cases (%) |
|------------------|---------------------|
| Business or Professional* | 101 (26.0)         |
| Casual Labourer | 1 (0.3)             |
| Farmer           | 35 (9.0)            |
| Health Worker   | 12 (3.1)            |
| Artisan          | 11 (2.8)            |

*Data based on state guidelines.*
symptom onset. Edo and Ondo states had a high number of cases captured within the surveillance system compared to the other states but did not have the longest presentation delays. The shorter presentation times in Edo and Ondo may be attributed to the historical high incidence of LF in these states leading to a higher index of suspicion and greater awareness among the population. Areas such as Nasarawa and Cross Rivers states, which had fewer cases but the longest presentation times, may benefit from more targeted risk communication and public health action. While the regression analysis did not show any factors associated with later

| Characteristic                          | Stratum                        | Number of cases (%) | Number of cases attending in 6 or less days (%) | Median time to presentation (days) | Interquartile range of time to presentation (days) | Range of time to presentation (days) |
|----------------------------------------|--------------------------------|---------------------|----------------------------------------------|----------------------------------|-----------------------------------------------|----------------------------------|
| Housewife                              | 32 (8.2)                       | 14 (43.8)           | 7                                            | 5–13                             | 1–21                                          |
| Religious or Traditional                  | 6 (1.5)                        | 2 (33.3)            | 7                                            | 5–7                              | 3–10                                          |
| Student or Child or Apprentice           | 126 (32.4)                     | 72 (57.1)           | 6                                            | 3–10                             | 1–21                                          |
| Transporter                            | 5 (1.3)                        | 1 (20.0)            | 9                                            | 7–10                             | 4–15                                          |
| Not working or Retired                   | 10 (2.6)                       | 4 (40.0)            | 8.5                                          | 3–12                             | 1–14                                          |
| Unknown                                | 50 (12.9)                      | 36 (72.0)           | 6                                            | 3–7                              | 1–21                                          |
| **Symptoms**                            |                                 |                     |                                              |                                  |                                               |
| Mild                                   | 123 (31.6)                     | 78 (63.4)           | 6                                            | 4–8                              | 1–21                                          |
| Severe                                 | 22 (5.7)                       | 12 (54.6)           | 6                                            | 3–8                              | 1–14                                          |
| Unknown                                | 244 (62.7)                     | 118 (48.4)          | 7                                            | 4–11                             | 1–21                                          |
| **First symptom**                      |                                 |                     |                                              |                                  |                                               |
| Mild                                   | 167 (42.9)                     | 83 (49.7)           | 7                                            | 4–11                             | 1–21                                          |
| Severe                                 | 2 (0.5)                        | 1 (50.0)            | 8                                            | 2–14                             | 2–14                                          |
| Unknown                                | 220 (56.6)                     | 124 (56.4)          | 6                                            | 4–9.5                            | 1–21                                          |
| **Exposure to confirmed case**          |                                 |                     |                                              |                                  |                                               |
| No                                     | 87 (22.4)                      | 43 (49.4)           | 7                                            | 4–9                              | 1–20                                          |
| Yes                                    | 39 (10.0)                      | 20 (51.3)           | 6                                            | 4–10                             | 1–20                                          |
| Unknown                                | 263 (67.6)                     | 145 (55.1)          | 6                                            | 4–10                             | 1–21                                          |
| **Exposure to rodents**                 |                                 |                     |                                              |                                  |                                               |
| No                                     | 8 (2.0)                        | 2 (25.0)            | 9                                            | 6.5–16                           | 3–20                                          |
| Yes                                    | 12 (3.1)                       | 4 (33.3)            | 8                                            | 6–12                             | 2–20                                          |
| Unknown                                | 369 (94.9)                     | 202 (54.7)          | 6                                            | 4–10                             | 1–21                                          |
| **Part of a contact tracing list**      |                                 |                     |                                              |                                  |                                               |
| No                                     | 124 (31.4)                     | 57 (46.0)           | 7                                            | 4.5–11                           | 1–21                                          |
| Yes                                    | 36 (9.8)                       | 19 (52.8)           | 6                                            | 3.5–10                           | 1–20                                          |
| Unknown                                | 229 (58.8)                     | 132 (57.6)          | 6                                            | 3–10                             | 1–21                                          |
| **History of travel**                   |                                 |                     |                                              |                                  |                                               |
| No                                     | 279 (71.7)                     | 148 (53.1)          | 6                                            | 4–10                             | 1–21                                          |
| Yes                                    | 86 (22.1)                      | 48 (55.8)           | 6                                            | 4–11                             | 1–20                                          |
| Unknown                                | 24 (6.2)                       | 12 (50.0)           | 6.5                                          | 3–13.5                           | 2–21                                          |
| **Attended a funeral**                  |                                 |                     |                                              |                                  |                                               |
| No                                     | 230 (59.1)                     | 124 (53.9)          | 6                                            | 3–10                             | 1–21                                          |
| Yes                                    | 1 (0.3)                        | 0                   | 11                                           | n/a                             | n/a                                           |
| Unknown                                | 158 (40.6)                     | 84 (53.2)           | 6                                            | 5–10                             | 1–21                                          |
| **Participated in a funeral (touched body)** |                         |                     |                                              |                                  |                                               |
| No                                     | 156 (40.1)                     | 75 (48.1)           | 7                                            | 4–10                             | 1–21                                          |
| Yes                                    | 4 (1.0)                        | 2 (50.0)            | 6                                            | 2–10                             | 2–13                                          |
| Unknown                                | 229 (58.9)                     | 131 (53.5)          | 6                                            | 4–10                             | 1–21                                          |

Includes only those that have a non-missing value for the time to presentation variable and the characteristic and for presentation times between 1 and 21 days

*a Business or professional: A business person here refers to one who earns profit by supplying goods and services while a professional refers to someone with specified qualifications or expertise who gets paid for rendering services. Religious or Traditional: Traditional healers use indigenous plants, herbs and the root of plants to heal sick people while religious healers use prayers predominantly to heal sick people

*No information for this state has been reported in this dataset
| Characteristic                          | Stratum       | Hazard ratio | Crude 95% CI | Crude p-value | Proportional Hazard test of assumption |
|----------------------------------------|---------------|--------------|--------------|---------------|----------------------------------------|
| **Sex**                                |               |              |              |               |                                        |
| Male                                   | Ref           | 0.97         | 0.28         |               |                                        |
| Female                                 | 1.10          | 0.82–1.23    |              |               |                                        |
| **Age (per year)**                     |               |              |              |               |                                        |
| 0–4                                    | Ref           | 1.00         | 0.99–1.01    | 0.95          | 0.05                                   |
| 5–12                                   | 1.08          | 0.60–1.89    |              |               |                                        |
| 13–17                                  | 1.25          | 0.71–2.21    |              |               |                                        |
| 18–25                                  | 0.91          | 0.55–1.53    |              |               |                                        |
| 26–59                                  | 0.97          | 0.61–1.53    |              |               |                                        |
| 60+                                    | 1.11          | 0.63–1.96    |              |               |                                        |
| **Mortality status**                   |               |              |              |               |                                        |
| Dead                                   | Ref           | 0.97         | 0.73–1.28    | 0.81          | 0.45                                   |
| Alive                                  | 1.10          | 0.73–1.28    |              |               |                                        |
| **Rurality**                           |               |              |              |               |                                        |
| Rural                                  | Ref           | 0.34         | 0.34         | 0.37          |                                        |
| Semi-urban                             | 1.39          | 0.79–2.46    |              |               |                                        |
| Urban                                  | 1.15          | 0.89–1.49    |              |               |                                        |
| **Malaria prevalence category**        |               |              |              |               |                                        |
| 0–11%                                  | Ref           | 0.37         | 0.37         | 0.88          |                                        |
| 12–21%                                 | 1.09          | 0.36–2.71    |              |               |                                        |
| 22–29%                                 | 4.15          | 0.74–23.44   |              |               |                                        |
| 30–36%                                 | 1.00          | 0.36–2.83    |              |               |                                        |
| 37–64%                                 | 0.85          | 0.28–2.64    |              |               |                                        |
| **Education status**                   |               |              |              |               |                                        |
| Primary                                | Ref           | 1.44         | 0.81–2.55    | 0.38          | 0.97                                   |
| Secondary                              | 1.11          | 0.63–1.91    |              |               |                                        |
| Tertiary                               | 1.11          | 0.63–1.91    |              |               |                                        |
| **Occupation group**                   |               |              |              |               |                                        |
| Not working or retired                 | Ref           | 0.95         | 0.95         | 0.65          |                                        |
| Student or Child or Apprentice         | 1.13          | 0.57–2.23    |              |               |                                        |
| Housewife                              | 0.89          | 0.42–1.88    |              |               |                                        |
| Farmer                                 | 1.21          | 0.58–2.54    |              |               |                                        |
| Casul labourer                         | 1.26          | 0.16–10.02   |              |               |                                        |
| Transporter                            | 0.91          | 0.30–2.72    |              |               |                                        |
| Religious or Traditional               | 1.45          | 0.51–4.10    |              |               |                                        |
| Artisan                                | 1.15          | 0.47–2.78    |              |               |                                        |
| Business or Professional               | 1.10          | 0.55–2.18    |              |               |                                        |
| Health Worker                          | 1.47          | 0.61–3.55    |              |               |                                        |
| **Symptom severity**                   |               |              |              |               |                                        |
| Mild                                   | Ref           | 0.90         | 0.90         | 0.61          |                                        |
| Severe                                 | 1.03          | 0.65–1.63    |              |               |                                        |
| **Exposure to rodents**                |               |              |              |               |                                        |
| No                                     | Ref           | 0.69         | 0.69         | 0.82          |                                        |
| Yes                                    | 1.23          | 0.45–3.34    |              |               |                                        |
| **Exposure to confirmed case**         |               |              |              |               |                                        |
| No                                     | Ref           | 0.77         | 0.77         | 0.93          |                                        |
| Yes                                    | 0.94          | 0.64–1.38    |              |               |                                        |
| **History of Travel**                  |               |              |              |               |                                        |
| No                                     | Ref           | 0.76         | 0.76         | 0.26          |                                        |
| Yes                                    | 1.04          | 0.81–1.34    |              |               |                                        |
| **Attended a funeral**                 |               |              |              |               |                                        |
| No                                     | Ref           | 0.79         | 0.79         | 0.35          |                                        |
| Yes                                    | 0.65          | 0.09–4.68    |              |               |                                        |
presentation, it is important to recognise that almost half of the cases presented 6 days after symptom onset. There may be a systemic reason for cases to present later which may not be evident from this study.

The findings of the Cox regression are somewhat unexpected, as other studies investigating health seeking behaviours, delays in diagnostics and presentation for other infectious and parasitic diseases have found significant associations with various factors. Ukwaja et al., 2013, found that factors associated with increased presentation delay in Nigeria for tuberculosis cases were older age, distance to a health facility and urban residency [13]. However, a study by Hulland et al., 2019 showed that in Nigeria, 98% of the population at risk of VHF had travel times to a health facility of under 2 h with exceptions of some states, so this may not be a factor for delayed presentation for LF [22]. In Zambia, Needham et al., 2001 found that there were significant socio-demographic factors associated with delay, including being female and only having an education up to the age of 9 years [11]. For Ebola disease, another VHF, Theocharopoulos et al., 2017, found that transportation time and age affected the time to admission for Ebola patients in Sierra Leone [23]. A common practice in Nigeria, particularly in Northern states, is for a woman to seek her husband’s consent before going out therefore not seeing an association with sex and time to presentation is unexpected [24].

We believe that our findings resulted in part from limitations of the surveillance data, including a lack of data from multiple years of outbreaks and high quality and complete epidemiological and exposure data. Education status was missing for almost 80% of the confirmed cases in our dataset, with no option provided for ‘no formal education’. Symptom data were missing for more than 60% of cases and exposure data was missing in up to 95% of cases. This limits the interpretation of our findings and potential interventions to be put into place. More years of surveillance data, collected in a consistent manner with higher completion rates for variables, may provide a clearer picture of factors associated with presentation delays, which may be important to inform public health messaging.

**Study limitations**

Firstly, this analysis was restricted to confirmed case records that had completed symptom onset and healthcare attendance dates (78% of confirmed cases); this may increase the risk of selection bias limiting the generalisability of the analysis. We compared cases with missing presentation times by age and sex in a logistic regression. For age group, there was no significant difference between those with and without presentation time, suggesting that the dates may be missing completely at random. However, for sex, there was a statistical difference, with males more likely to have missing presentation dates. Therefore, data may not be missing completely at random and may have introduced bias into our results.

Secondly, the completion of symptom onset dates varied across different LGA areas and/or health facilities. We decided to exclude dates where presentation time was 0 days or greater than 21 days. This may have excluded true data, but it is unlikely given the mild symptoms at onset and the likelihood of death or resolution after 21 days. A presentation time of 0 could have occurred if the case had known LF exposures or were part of a contact tracing list; but these fields were poorly completed.

Thirdly, underreporting in certain states may be an issue, with several states reporting little or no cases, which may not be a true indication of the incidence.

Finally, residual confounding could occur as only a few variables are currently collected for establishing presentation delay, which may limit interpretation of factors associated with delays.

**Future work**

To generate hypotheses, important gaps in LF surveillance data need to be addressed across all states of Nigeria. This requires a coordinated effort nationally and regionally. Detailed and complete information needs to be captured for clinical and exposure factors. This work is currently ongoing in Nigeria with the complete roll-out and use of the Surveillance Outbreak Response Management and Analysis System (SORMAS), which was partially rolled out at the time of this study (12 states). Further details around SORMAS are found elsewhere [25]. With the wider use of SORMAS, the linked electronic system allows improved data completion,
removes some of the traditional paper-based forms, improving the data quality and removing duplication of efforts. It is important that clear definitions are used throughout the system and across states. Following full implementation of SORMAS a detailed evaluation would improve understanding of any regional surveillance infrastructure issues or reporting biases. This may help explain some surveillance artefacts, such as high case numbers in some areas compared to others, that could affect interpretation of studies using this surveillance data. Further understanding on an association with mortality and delayed presentation would be worthwhile, which would require complete follow-up information on mortality status following confirmed LF diagnosis.

To reduce residual confounding, further data could be collected on social and structural factors such as health literacy level, homelessness, poverty, physical disability, similar to McQuilkin et al., 2017 in Liberia during the Ebola epidemic [26]. This will improve knowledge on healthcare access issues and attitudes during outbreaks. This may be difficult to establish and collect in routine surveillance.

Further quantitative and qualitative studies should be considered beyond routinely collected surveillance and collect data underpinned by frameworks of delays, such as the three-delays model [14, 15]. Adewole et al., 2017 collected data on other determinants of poor health seeking behaviour such as out of pocket payment, health insurance coverage and levels of self-treatment [27]. Although Hulland et al. [22] have done work in investigating travel times to a healthcare facility, a useful enhancement would be to collect information on travel time from residence to healthcare facility, to assess accessibility.

It is important to recognise that risk factors may change with time, so where plausible surveillance should be updated to capture additional risk factors for investigation.

Once outbreak surveillance data quality is improved over a series of LF outbreak years, this study can be repeated to generate further hypotheses. This will allow for targeted public health interventions such as education and risk communication to reduce the mortality of confirmed LF cases.

Conclusions

Whilst we observed important differences in presentation delays across factors, our study did not indicate a statistical association of any routinely collected factors with a delayed presentation of LF cases to a healthcare facility. Such associations may exist, but incomplete routine outbreak surveillance data may have hampered our ability to identify them. However, almost half of confirmed LF cases presented after 6 days of symptom onset, beyond the period in which ribavirin may be most effective. This highlights a need for improved national surveillance and studies to determine if there are systemic or specific causes for delays for LF and potentially other VHF cases. This information will help to inform, monitor, strengthen and evaluate risk communication and public health action strategies, to reduce the CFR associated with delayed care and treatment of LF cases.

Abbreviations

CFR: Case fatality rate; CI: Confidence Interval; IQR: Interquartile range; LF: Lassa fever; LGA: Local Government Area; NCDC: Nigeria Centre for Disease Control; RNA: Ribonucleic acid; SORMAS: Surveillance Outbreak Response Management and Analysis System; UK: United Kingdom; VHF: Viral haemorrhagic fever

Acknowledgements

We thank colleagues at all the LF Treatment Centres and testing laboratories, LGA Disease Surveillance and Notification Officers, State Epidemiologists, the LF Technical Working Group, colleagues at Nigeria Centre for Disease Control and the UK Public Health Rapid Support Team, and all partners who have been involved in surveillance and monitoring of LF in Nigeria. NLC thanks James Eton and Valerie Decraene from the UK Field Epidemiology Training Programme for their support.

Authors’ contributions

NLC, HB and CI had the original idea of the study. NLC, HB, CD, NV, SN, OL, EJ, GN, WU, AO, OlPdW, DGB and CI advised on the methods of undertaking the study. UO, SF and ES provided the data from the main contributing states. WU, AO, AI, MA, AA, KA were involved in the management, linkage, provided the collated dataset for analysis and advised on the use of the data. NLC undertook and interpreted the analyses. HB and NV advised on the analysis and interpretation. All authors read and approved the final version.

Funding

Nothing to declare.

Availability of data and materials

The data that support the findings of this study are available from Nigeria Centre for Disease Control but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Nigeria Centre for Disease Control.

Ethics approval and consent to participate

Ethical committee clearance was provided by the London School of Hygiene and Tropical Medicine Research Ethics Committee and the National Health Research Ethics Committee of Nigeria to undertake this study which uses retrospective routine data collected as part of LF surveillance in Nigeria. The Nigeria Centre for Disease Control collects data in line with the Disease Surveillance and Notification system using the Integrated Disease Surveillance and Response Strategy in Nigeria. Nigeria Centre for Disease Control shared the data with the first author of the manuscript from Public Health England in accordance with a data sharing agreement.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. The UK Public Health Rapid Support Team is funded by the United Kingdom Department of Health and Social Care. The views expressed in this publication are those of the authors and not necessarily those of the National Health System, the National Institute for Health Research, or the Department of Health and Social Care.
Author details

1 UK Field Epidemiology Training Programme, Public Health England, London, UK.
2 UK Public Health Rapid Support Team - Public Health England/London School of Hygiene & Tropical Medicine, London, UK.
3 Nigeria Centre for Disease Control, Abuja, Nigeria.
4 World Health Organization, Abuja, Nigeria.
5 Georgetown University, Centre for Global Health Practice and Impact, Abuja, Nigeria.
6 Edo State Ministry of Health, Edo, Nigeria.
7 Ondo State Ministry of Health, Ondo, Nigeria.
8 Ebonyi State Ministry of Health, Ebonyi, Nigeria.
9 Public Health England, National Infection Service, London, UK.

Received: 9 September 2020 Accepted: 19 January 2021
Published online: 04 February 2021

References

1. Centers for Disease Control and Prevention. Factsheet: Lassa Fever 2019 [Available from: https://www.cdc.gov/lassa/pdf/factsheet.pdf]. Accessed 25 July 2019.
2. World Health Organization. Lassa Fever: Factsheet 2017 [Available from: https://www.who.int/en/news-room/fact-sheets/detail/lassa-fever]. Accessed 25 July 2019.
3. Nigeria Centre for Disease Control. Diseases: Lassa Fever 2019 [Available from: https://necd.gov.ng/diseases/info/]. Accessed 25 July 2019.
4. Dan-Nwafor CC, Furuse Y, Iliori EA, Ipadeola O, Akabike KO, Ahumibe A, et al. Measures to control protracted large Lassa fever outbreak in Nigeria, 1 January to 28 April 2019. Eurosurveillance. 2019;24(20):1900272.
5. Nigeria Centre for Disease Control. 2019 Lassa Fever Outbreak Situation Report: Epi Week 21. 2019.
6. Nigeria Centre for Disease Control. 2018 Lassa Fever Outbreak Situation Report: Epi Week 21. 2018.
7. Nigeria Centre for Disease Control. 2017 Lassa Fever Outbreak Situation Report: Epi Week 51. 2017.
8. Eberhardt KA, Mischlingr J, Jordan S, Groger M, Günther S, Ramharter M. Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int J Infect Dis. 2019;87:15–20.
9. Richmond JK, Bagdole D. Lassa fever: epidemiology, clinical features, and social consequences. Bmj. 2003;327(7426):1271–5.
10. McCormick JB, King UJ, Webb PA, Scribner CL, Craven RB, Johnson KM, et al. Lassa fever. N Engl J Med. 1986;314(1):20–6.
11. Needham DM, Foster SD, Tomlinson G, Godfrey-Faussett P. Socio-economic, gender and health services factors affecting diagnostic delay for tuberculosis patients in urban Zambia. Trop Med Int Health. 2001;6(4):256–9.
12. Hasker E, Lumbala C, Mbo F, Mpanya A, Kande V, Lutumia P, et al. Health care-seeking behaviour and diagnostic delays for human African Trypanosomiasis in the Democratic Republic of the Congo. Trop Med Int Health. 2011;16(7):869–74.
13. Ukwaja KN, Abubu I, Nweke CO, Onyenwe EC. Healthcare-seeking behavior, treatment delays and its determinants among pulmonary tuberculosis patients in rural Nigeria: a cross-sectional study. BMC Health Serv Res. 2013;13(1):25.
14. Thaddeus S, Maine D. Too far to walk: maternal mortality in context. Soc Sci Med. 1994;38(8):1091–110.
15. Calvello EJ, Skog AP, Tenner AG, Wallis LA. Applying the lessons of maternal mortality reduction to global emergency health. Bull World Health Organ. 2015;93:17–23.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions